The re-import of penicillins or streptomycins in dosage forms to Canada shows a consistent upward trajectory from 2024 to 2028, reaching values from 403.55 to 459 thousand US dollars. This indicates a steady growth trend projected over these years. In comparison to 2023 figures, assumed to be slightly lower given the consistent growth, the annual increase manifests in an average year-on-year growth of around 3.6%, suggesting strong demand and reliance on these imports. The compound annual growth rate (CAGR) over this period is expected to be approximately 3.6%.
Future trends to watch for include potential changes in global trade policies, shifts in domestic production capacities, and developments in pharmaceutical manufacturing and sourcing. A keen eye on these factors can provide further insight into potential disruptions or accelerations in this growth trend.
